ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL
December 10, 2024Ascentage Pharma today announced that it has released olverembatinib in combination the company's investigational novel Bcl-2 inhibitor, lisaftoclax, in relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (R/R Ph+ ALL),.
Pharma Sources Insight January 2025
